Search | WHO COVID-19 Research Database

1.

T cell responses to SARS-CoV-2 vaccination in people with multiple sclerosis differ between disease-modifying therapies

Wolf, A. S.; Ravussin, A.; Konig, M.; Overas, M. H.; Solum, G.; Kjonstad, I. F.; Chopra, A.; Holmoy, T.; Harbo, H. F.; Syversen, S. W.; Jorgensen, K. K.; Hogestol, E. A.; Vaage, J. T.; Celius, E. G.; Lund-Johansen, F.; Munthe, L. A.; Nygaard, G. O.; Mjaaland, S..

European Journal of Immunology ; 52:49-49, 2022.

Article in English | Web of Science | ID: covidwho-2237028

2.

Immunogenicity, efficacy and safety of mRNA-COVID-19 vaccines in people with multiple sclerosis

Konig, M.; Wolf, A. S.; Ravussin, A.; Chopra, A.; Tran, T. T.; Torgauten, H. M.; Rasmussen, T.; Schikora-Rustad, S.; Overas, M. H.; Lorentzen, R.; Aaberge, I. S.; Myhr, K. M.; Wergeland, S.; Aarseth, J. H.; Bo, L.; Berge, T.; Hogestol, E. A.; Harbo, H. F.; Tveter, A. T.; Jorgensen, K. K.; Torkildsen, O. F.; Holmoy, T.; Celius, E. G.; Vaage, J. T.; Munthe, L. A.; Mjaaland, S.; Lund-Johansen, F.; Nygaard, G. O..

Multiple Sclerosis Journal ; 28(3 Supplement):956-957, 2022.

Article in English | EMBASE | ID: covidwho-2138923

3.

Serologic Response to Sars-Cov-2 Vaccination in Patients with Inflammatory Bowel Disease on Immunosuppressive Therapy: Association to Disease Type and Serum Drug Levels

Jorgensen, K. K.; Hoivik, M. L.; Chopra, A.; Benth, J. S.; Ricanek, P.; Moum, B.; Jyssum, I.; Bolstad, N.; Warren, D.; Vaage, J. T.; Munthe, L. A.; Lundin, K. E. A.; Anisdahl, K.; Syversen, S. W.; Lovik Goll, G.; Lund-Johansen, F.; Medhus, A. W.; Jahnsen, J..

United European Gastroenterology Journal ; 10(Supplement 8):109, 2022.

Article in English | EMBASE | ID: covidwho-2114567

4.

The Persistence of Anti-Spike Antibodies Following Two Sars-Cov-2 Vaccines in Patients with Inflammatory Bowel- and Joint Diseases on Immunosuppressive Therapy Compared to Healthy Controls - a Prospective Cohort Study

Jorgensen, K. K.; Christensen, I. E.; Jyssum, I.; Tveter, A. T.; Sexton, J.; Tran, T.; Mjaaland, S.; Kro, G.; Kvien, T. K.; Warren, D.; Jahnsen, J.; Munthe, L. A.; Haavardsholm, E. A.; Vaage, J. T.; Grodeland, G.; Lund-Johansen, F.; Syversen, S. W.; Lovik Goll, G.; Provan, S. A..

United European Gastroenterology Journal ; 10(Supplement 8):740-741, 2022.

Article in English | EMBASE | ID: covidwho-2114566

5.

The antibody response to bnt162b2 or mrna-1273 vaccines in allotransplant recipients depends on the existing response to endemic human coronaviruses and previous atg therapy

Tvedt, T. H. A.; Gedde-Dahl, T.; Bruserud, O.; Abrahamsen, I. W.; Lund-Johansen, F.; Myhre, A. E..

Bone Marrow Transplantation ; 57(SUPPL 1):258-258, 2022.

Article in English | Web of Science | ID: covidwho-2112383

6.

THE PERSISTENCE of ANTI-SPIKE ANTIBODIES FOLLOWING TWO SARS-COV-2 VACCINES in PATIENTS with IMMUNE-MEDIATED INFLAMMATORY DISEASES USING IMMUNOSUPPRESSIVE THERAPY, COMPARED to HEALTHY CONTROLS

Egeland Christensen, I.; Jyssum, I.; Tveter, A. T.; Sexton, J.; Tran, T. T.; Mjaaland, S.; Kro, G. B.; Kvien, T. K.; Worren, D.; Jahnsen, J.; Munthe, L. A.; Haavardsholm, E.; Vaage, J. T.; Grodeland, G.; Lund-Johansen, F.; Jørgensen, K. K.; Syversen, S. W.; Goll, G. L.; Aarrestad Provan, S..

Annals of the Rheumatic Diseases ; 81:116-117, 2022.

Article in English | EMBASE | ID: covidwho-2008931

7.

SEROLOGICAL RESPONSE and SAFETY of A THREE-DOSE SARS-COV-2 VACCINATION STRATEGY in PATIENTS with IMMUNEMEDIATED INFLAMMATORY DISEASES on IMMUNOSUPPRESSIVE THERAPY

Jyssum, I.; Tveter, A. T.; Sexton, J.; Christensen, I. E.; Tran, T. T.; Mjaaland, S.; Warren, D. J.; Kvien, T. K.; Bjørlykke, K. H.; Kro, G. B.; Jahnsen, J.; Munthe, L. A.; Haavardsholm, E. A.; Vaage, J. T.; Grodeland, G.; Lund-Johansen, F.; Aarrestad Provan, S.; Jørgensen, K. K.; Goll, G. L.; Syversen, S. W..

Annals of the Rheumatic Diseases ; 81:127-128, 2022.

Article in English | EMBASE | ID: covidwho-2008875

8.

Immune response and safety in standard and third dose SARS-CoV-2 vaccination in patients with autoimmune hepatitis on immunosupressive therapy, a prospective cohort study

Jorgensen, K.; Chopra, A.; Sexton, J.; Tveter, A. T.; Hov, J. R.; Jyssum, I.; Nissen-Meyer, L. S. H.; Vaage, J. T.; Syversen, S. W.; Goll, G. L.; Lund-Johansen, F.; Jahnsen, J..

Journal of Hepatology ; 77:S309-S310, 2022.

Article in English | Web of Science | ID: covidwho-1980675

9.

IMMUNOGENICITY AND SAFETY OF STANDARD AND THIRD DOSE SARS-COV-2 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES;A PROSPECTIVE COHORT STUDY

Joergensen, K. K.; Syversen, S. W.; Jyssum, I.; Tveter, A. T.; Tran, T. T.; Sexton, J.; Provan, S. A.; Mjaaland, S.; Warren, D. J.; Kvien, T. K.; Gr⊘deland, G.; Nissen-Meyer, L. S. H.; Ricanek, P.; Chopra, A.; Anderson, A. M.; Kro, G. B.; Munthe, L. A.; Haavardsholm, E. A.; Vaage, J. T. T.; Lund-Johansen, F.; Jahnsen, J.; Goll, G. L..

Gastroenterology ; 162(7):S-287, 2022.

Article in English | EMBASE | ID: covidwho-1967277

10.

Immune Responses to COVID-19 Vaccines in Patients Using Immuno-suppressive Medication for Inflammatory Arthritis - An Observational Study of 1500 Patients

Jyssum, I.; Tveter, A. T.; Lund-Johansen, F.; Munthe, L.; Provan, S.; Jorgensen, K.; Grodeland, G.; Kro, G.; Warren, D.; Sexton, J.; Kvien, T.; Mjaaland, S.; Haavardsholm, E.; Vaage, J. T.; Syversen, S. W.; Goll, G..

Arthritis & Rheumatology ; 73:3240-3241, 2021.

Article in English | Web of Science | ID: covidwho-1728246

11.

Immunogenicity and safety of standard and third dose SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases;a prospective cohort study

Jørgensen, K. K.; Syversen, S. W.; Jyssum, I.; Tveter, A. T.; Tran, T. T.; Sexton, J.; Provan, S. A.; Mjaaland, S.; Warren, D. J.; Kvien, T. K.; Grødeland, G.; Nissen-Meyer, L. S.; Ricanek, P.; Chopra, A.; Andersson, A. M.; Kro, G. B.; Jahnsen, J.; Munthe, L. A.; Haavardsholm, E. A.; Vaage, J. T.; Lund-Johansen, F.; Goll, G. L..

Journal of Crohn's and Colitis ; 16:i537-i538, 2022.

Article in English | EMBASE | ID: covidwho-1722348

12.

Humoral and cellular immune responses to SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

Konig, M.; Lorentzen, A.; Tran, T.; Schikora-Rustad, S.; Leiknes, I. J.; Vaage, E. B.; Mygland, A.; Aaberge, I. S.; Berge, T.; Skattebol, L.; Harbo, H. F.; Andersen, J. T.; Vaage, J. T.; Celius, E. G.; Munthe, L. A.; Lund-Johansen, F.; Nygaard, G. O..

Multiple Sclerosis Journal ; 27(2 SUPPL):561, 2021.

Article in English | EMBASE | ID: covidwho-1495947

13.

A Norwegian study of immune responses to coronavirus disease 2019 (COVID-19) vaccines in patients using immunosuppressive medication within rheumatology: The Nor-vaC study

Jyssum, I.; Tveter, A. T.; Lund-Johansen, F.; Munthe, L. A.; Provan, S. A.; Jørgensen, K. K.; Grødeland, G.; Kro, G. B.; Warren, D. J.; Sexton, J.; Mjaaland, S.; Haavardsholm, E. A.; Vaage, J. T.; Syversen, S. W.; Goll, G. L..

Scandinavian Journal of Rheumatology ; 50(SUPPL 130):37-38, 2021.

Article in English | EMBASE | ID: covidwho-1447446

SEND TO:

SELECTION OF CITATIONS

SEARCH DETAIL